ALKERMES | Passivo Circulante



Current Liabilities Alterar Data
AbbVie USD 38.75B 4.31B 2024-12
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
ALKERMES USD 465.2M 11.5M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
Gilead Sciences USD 12B 279M 2024-12
Intra Cellular Therapies USD 205.7M 39.59M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
J&J USD 50.32B 1.44B 2024-12
Malin Corporation EUR 500K 500K 2024-06
Merck USD 28.42B 1.17B 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Otsuka Holdings JPY 632.66B 114.36B 2024-12
Pfizer USD 43B 216M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



ALKERMES Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2025.